IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET

Company Participants

Fred Schwarzer – Chief Executive Officer

Misbah Tahir – Chief Financial Officer

Chris Takimoto – Chief Medical Officer

Mary Beth Harler – President-IGM Autoimmunity and Inflammation

Bruce Keyt – Chief Scientific Officer

Conference Call Participants

Stephen Willey – Stifel

Greg Harrison – Bank of America

Michael Schmidt – Guggenheim

Roger Song – Jefferies

Joel Beatty – Baird

Noah Eisenberg – JPMorgan

Leonid Timashev – RBC Capital Markets

Asthika Goonewardene – Truist

Operator

Good day, everyone, and welcome to the IGM Biosciences’ Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Today's call is being recorded.

At this time, I would like to turn the call over to Fred Schwarzer, Chief Executive Officer of IGM.

Fred Schwarzer

Thank you, operator. And thanks to all of you joining us on this call.

On behalf of IGM, I'm joined today by Misbah Tahir, Chief Financial Officer; Dr. Chris Takimoto, Chief Medical Officer; Dr. Bruce Keyt, Chief Scientific Officer; and Dr. Mary Beth Harler, President, IGM Autoimmunity and Inflammation.

Please note that we will be making forward-looking statements on this call including statements about IGM's plans, expectations and forecasts and about future events. Actual results may differ materially as a result of various risks and uncertainties including those discussed in the Company's most recent annual report on Form 10-K as well as its other filings with the SEC.

Any forward-looking statements represent IGM's views as of today, March 30, 2023 only, and the Company disclaims any obligation to update these statements, except as required by law.

Following this call, a replay will be available on the Company's website, www.igmbio.com.

I would like to start with a few introductory remarks and then I will turn the call over to Misbah to take you through our 2022 financial results. After Misbah's update, Chris will update you on clinical development of IGM-8444, our death receptor 5 agonist antibody. Next, Mary Beth will update you on our development plans for Imvotamab and autoimmune diseases. We will then turn it back over to Chris to discuss the two most recent product candidates in our oncology pipeline, IGM-7354, our IGM targeted immunostimulatory IL-15 cytokine; and IgM-2644, our CD38/CD3 T cell engager, a next generation CD38 antibody for multiple myeloma.

Looking back, 2022 was a transformational year for IGM. At the end of the first quarter, we entered into an important collaboration with Sanofi to develop novel IgM agonist antibodies to address three oncology targets and three autoimmune targets. Throughout the year we also continued the clinical development of our death receptor 5 agonist antibody, IGM-8444, particularly in combination with FOLFIRI for the treatment of colorectal cancer.